Evidence map›Paper›PMID 40984949›Full record

ArticleCureus2025

A Challenging Diagnosis of Laryngeal Neuroendocrine Tumor (NET): Final Classification as NET Grade 3 After Total Laryngectomy.

Naoya Sanda, Nayuta Tsushima, Hayato Imanari, Akihiro Homma

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Naoya SandaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JPN.
Nayuta TsushimaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JPN.
Hayato ImanariDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JPN.
Akihiro HommaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laryngeal neuroendocrine neoplasms (NENs) are rare tumors that account for a small proportion of all laryngeal malignancies. They exhibit a wide range of differentiation and proliferative activity, and are often graded accordingly, using markers such as mitotic count and Ki-67 labeling index. We present the case of a 76-year-old man with progressive dysphagia and a supraglottic mass. Initial biopsy findings were inconclusive, raising suspicion of poorly differentiated carcinoma or metastatic disease. A re-biopsy of the larynx under general anesthesia and neck dissection revealed features consistent with neuroendocrine tumor (NET) Grade 2 (Ki-67 index 17%). Due to the limited efficacy of nonsurgical treatments and absence of somatostatin receptor expression, total laryngectomy was performed. Histopathological analysis of the resected specimen demonstrated increased mitotic activity and a Ki-67 index of 28%, leading to a revised diagnosis of NET Grade 3. This case highlights the diagnostic limitations of small biopsy specimens in the head and neck region and underscores the importance of stepwise evaluation, including surgical pathology, in establishing an accurate diagnosis and guiding curative treatment decisions in rare laryngeal NETs.

Indexed as

cancer of the head and necklaryngeal tumorsneuroendocrine carcinoma (nec)neuroendocrine neoplasmneuroendocrine tumors (net)total laryngectomy

Identifiers

PMID40984949
PMCPMC12450322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.